AbbVie (NYSE:ABBV) Stock Price Down 2.4% - What's Next?

AbbVie logo with Healthcare background
Image from MarketBeat Media, LLC.

AbbVie Inc. (NYSE:ABBV - Get Free Report) was down 2.4% during mid-day trading on Wednesday. The stock traded as low as $284.91 and last traded at $285.9170. 4,735,965 shares changed hands during mid-day trading, a decline of 25% from the average session volume of 6,277,263 shares. The stock had previously closed at $292.82.

Key Stories Impacting AbbVie

Here are a few of the latest stories about ABBV:

  • Positive Sentiment: AbbVie’s neuroscience franchise posted 19.5% operational sales growth in Q3, and the company raised its 2026 sales outlook for the segment to $13 billion—supportive signs for growth beyond its established products. How Did AbbVie's Neuroscience Franchise Perform in Q3?
  • Neutral Sentiment: AbbVie reported an update to its ABBV-2294 clinical study for rare systemic sclerosis. The available summary does not provide trial results, so the update’s potential impact on the drug’s prospects is unclear. AbbVie Advances ABBV-2294 Study for Rare Systemic Sclerosis
  • Neutral Sentiment: Brokerages’ consensus price target was reported at $297.85. That is above the share price cited in the market background, but the consensus figure is less bullish than Barclays’ $335 target. AbbVie Stock Has Consensus Target Price of $297.85

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Leerink Partners raised their price target on shares of AbbVie from $309.00 to $342.00 and gave the company an "outperform" rating in a research report on Monday, November 2nd. Scotiabank upped their price objective on shares of AbbVie from $280.00 to $320.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 6th. Weiss Ratings upgraded shares of AbbVie from a "buy (b-)" rating to a "buy (b)" rating in a research note on Thursday, October 8th. JPMorgan Chase & Co. increased their price objective on shares of AbbVie from $285.00 to $300.00 and gave the company an "overweight" rating in a research note on Thursday, October 8th. Finally, The Goldman Sachs Group lifted their target price on shares of AbbVie from $258.00 to $294.00 and gave the stock a "neutral" rating in a research report on Friday, October 23rd. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat.com, AbbVie presently has a consensus rating of "Moderate Buy" and a consensus price target of $299.62.

Read Our Latest Analysis on AbbVie

AbbVie Price Performance

The business's fifty day moving average is $277.14 and its 200-day moving average is $241.64. The firm has a market cap of $505.39 billion, a PE ratio of 49.21, a P/E/G ratio of 1.34 and a beta of 0.20.

AbbVie (NYSE:ABBV - Get Free Report) last released its earnings results on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, beating analysts' consensus estimates of $3.73 by $0.09. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The firm had revenue of $17.40 billion for the quarter, compared to analysts' expectations of $17.32 billion. During the same period in the previous year, the company earned $1.86 earnings per share. The company's quarterly revenue was up 10.3% on a year-over-year basis. Analysts forecast that AbbVie Inc. will post 13.98 EPS for the current year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be paid a $1.82 dividend. The ex-dividend date is Friday, January 15th. This is a boost from AbbVie's previous quarterly dividend of $1.73. This represents a $7.28 annualized dividend and a dividend yield of 2.5%. AbbVie's dividend payout ratio is presently 119.10%.

Insider Activity at AbbVie

In other news, EVP Jeffrey Stewart sold 40,619 shares of the company's stock in a transaction on Monday, November 9th. The stock was sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the transaction, the executive vice president owned 83,171 shares of the company's stock, valued at $24,419,005.60. This represents a 32.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On AbbVie

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ABBV. Verus Financial Partners Inc. increased its stake in AbbVie by 1.7% during the third quarter. Verus Financial Partners Inc. now owns 2,048 shares of the company's stock worth $536,000 after purchasing an additional 35 shares during the period. Evergreen Private Wealth LLC boosted its stake in shares of AbbVie by 3.3% in the third quarter. Evergreen Private Wealth LLC now owns 1,090 shares of the company's stock valued at $285,000 after purchasing an additional 35 shares during the period. Lifelong Wealth Advisors Inc. boosted its stake in shares of AbbVie by 2.1% in the third quarter. Lifelong Wealth Advisors Inc. now owns 1,755 shares of the company's stock valued at $459,000 after purchasing an additional 36 shares during the period. IMG Wealth Management Inc. grew its holdings in shares of AbbVie by 22.8% in the third quarter. IMG Wealth Management Inc. now owns 194 shares of the company's stock valued at $51,000 after purchasing an additional 36 shares in the last quarter. Finally, Foundry Financial Group Inc. grew its holdings in shares of AbbVie by 4.6% in the third quarter. Foundry Financial Group Inc. now owns 839 shares of the company's stock valued at $219,000 after purchasing an additional 37 shares in the last quarter. Institutional investors own 70.23% of the company's stock.

AbbVie Company Profile

(Get Free Report)

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in AbbVie Right Now?

Before you consider AbbVie, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.

While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Related Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines